Meta-analysis on safety and immunogenicity of domestic inactivated quadrivalent influenza vaccine in people over three years old
10.13200/j.cnki.cjb.004239
- VernacularTitle:3岁以上人群接种国产四价流感病毒灭活疫苗安全性和免疫原性的Meta分析
- Author:
DENG Peng
- Publication Type:Journal Article
- Keywords:
Inactivated quadrivalent influenza vaccine;
Safety;
Immunogenicity;
Meta-analysis
- From:
Chinese Journal of Biologicals
2024;37(6):703-709+717
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and immunogenicity of domestic inactivated quadrivalent influenza vaccine(QIV)in people over three years old by using Meta-analysis,in order to provide evidence-based basis for formulating QIV immunization strategy in China.Methods Literature was retrieved by PubMed,EMBASE,Cochrane Library,China Biology Medicine disc(CBMd),Wanfang Database and China National Knowledge Infrastructure(CNKI).All the studies were the random control trials for comparing and analyzing the safety and immunogenicity between domestic QIV and inactivated trivalent influenza vaccine(TIV)for people over three years old.Meta-analysis of the included literature data was performed using Stata1 1.0 software.Results A total of four pieces of literature were included.Compared with TIV,the combined effect value risk ratio(RR)of local and systemic reactions in QIV was 1.10(95% CI:0.88-1.38,I~2= 0,P = 0.809)and 0.97(95% CI:0.87-1.09,I~2= 0,P = 0.485),respectively.Compared with TIV,the RR of seroconversion rate(SCR)and seroprotection rate(SPR)of QIV for the same vaccine strains were 0.98-1.06 and 0.98-1.02,respectively,with no significant difference(I~2were 28.8%-89.9% and 0-80.2%,respectively,each P > 0.05);However,there were significant differences between TIV and QIV for the B vaccine strains not included in TIV.The RR of SCR and SPR for B/Victoria were2.88(95% CI:1.75-4.74,I~2= 98.3%,P < 0.001)and 1.64(95% CI:1.16-2.33,I~2= 99.3%,P < 0.001),while for B/Yamagata were 1.89(95% CI:1.57-2.27,I~2= 94.4%,P < 0.001)and 1.15(95% CI:1.04-1.28,I~2= 98.4%,P < 0.001),respectively.Conclusion For people over three years old,domestic QIV not only produced similar safety and immunogenicity levels to TIV,but also had better immune effect against influenza B vaccine strains not included in TIV.
